Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-25 lentiviral vector is a gene therapy tool designed to overexpress microRNA-25 (miR-25) within target cells. In research concerning Acute Myeloid Leukemia (AML), miR-25 has been identified as a component of the miR-106b-25 cluster that contributes to chemoresistance and the evasion of apoptosis. The vector functions by delivering the miR-25 sequence, which subsequently targets and downregulates the expression of pro-apoptotic factors, specifically BAK1 and Caspase-7. This tool is primarily utilized in preclinical studies to model the oncogenic effects of miR-25 and to evaluate its impact on drug sensitivity in leukemic cell lines and xenograft models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-25 lentiviral vector.